Tina Rizack

Medical Marijuana Use in Oncology

Gianna Wilkie, Bachir Joseph Sakr, Tina Rizack · JAMA Oncology · 2016 · 95 citations

Medicine, Oncology, Pharmacology +17

A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study

Bradley J. Monk, Mark F. Brady, Carol Aghajanian et al. · Annals of Oncology · 2017 · 93 citations · Full text

Medicine, Oncology, Pharmacology +17

Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer – An NRG oncology/Gynecologic Oncology Group study

Vivian E. von Gruenigen, Helen Huang, Jan H. Beumer et al. · Gynecologic Oncology · 2017 · 83 citations · Full text

Medicine, Gynecology, Oncology +16

Survival of Patients with Squamous Cell Malignancies of the Upper Urinary Tract

David Berz, Tina Rizack, Sherry Weitzen et al. · Clinical Medicine Insights Oncology · 2011 · 38 citations · Full text

Medicine, Oncology, Urology +16

A phase II, randomized, double-blind, placebo-controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: A Gynecologic Oncology Group partners study

B.J. Monk, M.F. Brady, Carol Aghajanian et al. · Gynecologic Oncology · 2017 · 32 citations

Medicine, Oncology, Pharmacology +17